Combination therapies improve success of lung cancer treatment
Any fight is easier to face with backup. And there are few more formidable foes than cancer. For some time, doctors have tackled lung cancers caused by a mutation in a particular gene, KRAS, with drugs that inhibit that gene’s impact. However, although these treatments can knock back the threat, it often bounces back, making these cases of lung cancer particularly dangerous. A new approach tried providing those inhibitors with backup, attacking not just that aspect of the cancer, but two other mechanisms as well. On tests in mice, the three-pronged approach successfully shrank lung tumours (right after treatment, with each colour representing a different tumour), and kept them small, while tumours in mice that received just the KRAS inhibitors tended to return. The study found similarly promising results in tests with human cells, suggesting this approach may help stack the odds against this deadly form of lung cancer.
Written by Anthony Lewis
BPoD stands for Biomedical Picture of the Day. Managed by the MRC London Institute of Medical Sciences the website aims to engage everyone, young and old, in the wonders of biomedicine. Images are kindly provided for inclusion on this website through the generosity of scientists across the globe.
BPoD is also available in Catalan at www.bpod.cat with translations by the University of Valencia.